Abstract Number: 2414 • ACR Convergence 2024
A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased prevalence of cardiovascular risk factors (RFs), which predispose to higher risk of premature atherosclerotic cardiovascular disease…Abstract Number: 0701 • ACR Convergence 2024
Diagnostic Performances of Vascular Biomarkers Soluble Fms-like Tyrosine Kinase (sFlt-1) and Placental Growth Factor (PlGF) in Scleroderma Renal Crisis: A Case Control Study
Background/Purpose: Scleroderma renal crisis (SRC) is a major vascular complication of systemic sclerosis (SSc), associated with high morbidity and mortality. Few biomarkers are available to predict…Abstract Number: 2433 • ACR Convergence 2024
Sequential Pneumococcal Vaccination in SLE: Immunogenicity, Side Effects and Comparison with PPSV23 Vaccination
Background/Purpose: SLE patients have increased risk of invasive pneumococcal disease due to immune dysregulation and drugs used in these patients. EULAR 2019 recommendation suggest sequential…Abstract Number: 0844 • ACR Convergence 2024
Effectiveness and Safety of the Recombinant Zoster Vaccine in Patients ≥18 Years of Age with Systemic Lupus Erythematosus or Multiple Sclerosis
Background/Purpose: The recombinant zoster vaccine (RZV) is US Food and Drug Administration-approved for the prevention of herpes zoster (HZ, shingles) in adults ≥50 years, and…Abstract Number: 2588 • ACR Convergence 2024
Examining the Influence of Socioeconomic Status on Osteoarthritis Prevalence and Risk Factors Among New York Residents
Background/Purpose: Osteoarthritis (OA) is a chronic, progressive condition affecting the musculoskeletal system, significantly impacting the quality of life and mobility of millions worldwide. It is…Abstract Number: 0209 • ACR Convergence 2023
Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies
Background/Purpose: Safety and efficacy of updated bivalent vaccines, containing both the original vaccine variant of SARS-CoV-2 Spike and either Omicron variants BA.1 or BA.4/5, are…Abstract Number: 1801 • ACR Convergence 2023
Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) and particularly those treated with B-cell-depleting agents frequently fail to develop humoral responses to SARS-CoV-2 vaccinations and have…Abstract Number: 0217 • ACR Convergence 2023
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…Abstract Number: 1848 • ACR Convergence 2023
Demographic and Clinical Factors Associated with HPV Vaccination in Young Adults with Rheumatic Disease
Background/Purpose: The HPV vaccine is safe and immunogenic in RD patients but uptake is suboptimal. We aimed to evaluate factors associated with HPV vaccination in…Abstract Number: 0219 • ACR Convergence 2023
Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab
Background/Purpose: Patients on B-cell depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting SARS-CoV-2 or suffering from…Abstract Number: 1856 • ACR Convergence 2023
Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project
Background/Purpose: Herpes zoster is a painful rash that involves one to three adjacent dermatomes, secondary to reactivation of latent varicella-zoster virus (VZV). About 95 %…Abstract Number: 0616 • ACR Convergence 2023
Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study
Background/Purpose: Systemic Sclerosis is an autoimmune disorder marked by thickened and hardened skin. Cutaneous cutis, the deposition of insoluble calcium salts in the skin and…Abstract Number: 1895 • ACR Convergence 2023
Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies
Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of cardiovascular disease (CVD). Despite multiple CVD risk tools available, reliability to RA population is…Abstract Number: 0742 • ACR Convergence 2023
Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a revolutionary second-line treatment for type 2 diabetes associated with lower risk of cardiovascular and all-cause mortality, heart failure,…Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »